# When a GLP-1 feels less effective: hunger and weight trends

A change in appetite or a pause in weight loss needs a broader review. Treatment response includes weight trends, tolerability and health goals.

Canonical: https://velri.co/blog/glp1-feels-like-stopped-working-provider-review-deshawn
Publisher: Velri (https://velri.co/about)
Published: 2026-06-22
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

A return of hunger or a pause in weight loss does not, by itself, establish that a GLP-1 medicine has stopped working. Medication response is assessed over time, including weight change, side effects and the goals of treatment. Continued treatment may also help maintain a loss rather than produce a lower weight indefinitely. [1][2]

## Appetite and weight are related, but different

Semaglutide and tirzepatide affect appetite and calorie intake. That helps explain why the experience of hunger may change during treatment. [3][4]

A 60-week semaglutide trial found that reduced laboratory food intake persisted even when some subjective appetite benefits were no longer significantly different from placebo. Feeling less appetite suppression therefore did not mean every measured treatment effect had disappeared. [5]

A useful description distinguishes stronger hunger from more frequent food thoughts, different portions, or a weight trend that has leveled off.

## Look at the course of treatment

NIDDK describes medication choice and continuation as decisions based on benefits, side effects, other health issues and cost. Its guidance also notes that response varies among people. [1]

A review can consider the weight trend, the exact product, how it has been taken and whether side effects make regular eating or drinking difficult. The approved labels direct clinicians to consider treatment response and tolerability when selecting maintenance treatment. [3][4]

## Maintenance can be an active result

In the SURMOUNT-4 trial, adults who had completed an initial tirzepatide treatment period were randomized either to continue it or switch to placebo. Continued treatment maintained and added to the initial weight reduction, while withdrawal led to substantial regain on average. [2]

The study supports maintenance as a meaningful treatment outcome. Treatment changes still depend on the person's response and tolerability. [1][2]

Bring the actual trend and the specific change in appetite to the review. The useful question is whether the current plan is still meeting its purpose, and what evidence would justify changing it.

## Sources
[1] Prescription Medications to Treat Overweight & Obesity - NIDDK (2025). https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
[2] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. (2024). https://pubmed.ncbi.nlm.nih.gov/38078870/
[3] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[4] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[5] Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42323166/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support